Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
CRMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.61 - $13.85
Previous CloseN/A
Volume1.29M
Average Volume (3M)1.69M
Market Cap
$395.65M
Enterprise Value$447.05M
Total Cash (Recent Filing)$35.26M
Total Debt (Recent Filing)$631.39K
Price to Earnings (P/E)―
Beta1.92
Next Earnings
May 08, 2025EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding65,181,770
10 Day Avg. Volume3,453,235
30 Day Avg. Volume1,694,885
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)53.99
Price to Cash Flow (P/CF)-12.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.10
Enterprise Value/Ebitda-23.69
Forecast
1Y Price Target
$16.00Price Target Upside153.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Cormedix News
PremiumCompany Announcements
CorMedix Inc. Reports Record Q4 Earnings and Growth
PremiumCompany Announcements
CorMedix Inc. Achieves Profitability with DefenCath Launch---
Bulls Say, Bears Say
Bulls Say
Product LaunchThere remains a positive outlook on DefenCath’s US launch and beyond.
Sales PerformanceCRMD reported preliminary DefenCath sales significantly above Street expectations.
Bears Say
Partnership ChallengesNegotiations with the other large dialysis organization appear to be at a standstill.
Sales ForecastSales are expected to dip, which is lower than expected.
Stock PerformanceCRMD shares are under pressure, down approximately 26%, following their earnings update.
---
Ownership Overview
2.34% Insiders
8.26% Mutual Funds
9.92% Other Institutional Investors
68.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $3.61 and its highest was $13.85 in the past 12 months.
What is Cormedix’s market cap?
Cormedix’s market cap is $395.65M.
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is May 08, 2025 which is in 35 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Mar 25, 2025. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.132 by $0.088.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is 0.19.
How many shares outstanding does Cormedix have?
Cormedix has 65,181,770 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of $0.22 in its last earnings report, beating expectations of $0.132. Following the earnings report the stock price went down -31.848%.
Which hedge fund is a major shareholder of Cormedix?
Currently, no hedge funds are holding shares in CRMD
---
Cormedix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (153.97% Upside)
$16.00 (153.97% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.41%
12-Months-Change
Fundamentals
Return on Equity
-23.17%
Trailing 12-Months
Asset Growth
44.83%
Trailing 12-Months
Company Description
Cormedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company operates in the healthcare sector and its core product is DefenCath, an antibacterial and antifungal solution designed to prevent catheter-related bloodstream infections in patients undergoing hemodialysis.
---
CRMD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
CorMedix reported a strong financial performance with record-breaking revenue and profitability in Q4 2024, driven by success in the outpatient segment and growth in the inpatient segment. However, challenges such as anticipated net price erosion, delayed LDO implementation, increased operating expenses, and slower progress with expanding the customer base present potential hurdles. Overall, the highlights of financial growth and strategic progress are significant, but the lowlights indicate some critical areas needing attention.Read More>---
CRMD Stock 12 Month Forecast
Average Price Target
$16.00
▲(153.97% Upside)
Technical Analysis
Best Analysts Covering CRMD
1 Year
1 Year Success Rate
14/24 ratings generated profit
1 Year Average Return
+23.00%
reiterated a buy rating 10 days ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +23.00% per trade.
---